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An enzyme-linked immunosorbent assay has been developed to detect human C5a antigen. This 
ELISA methodology has been shown to be a highly sensitive technique capable of detecting C5a antigen 
concentrations below 10 ng/ml. The microELIS.4 technique used in this study is specific for human C5a 
and C5a des arg (C5a antigen) but not for human C5. Conditions to establish sensitivity and specificity 
are outlined in this report. 
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Introduction 
Enzymatic cleavage or the third and fifth components of complement by activa- 
tion of either the classical or alternative pathway yields 2 low molecular weight 
peptides historically referred to as anaphylatoxins. The potent biological activities of 
the complement-derived anaphylatoxins, C3a and C5a, have been well documented 
and include histamine release from mast cells (Johnson et al., 1975) smooth muscle 
contraction (Cochrane et al., 1968), and increase in capillary permeability (Vallota 
and Muller-Eberhard, 1973). A further functional attribute of the C5a peptide that is 
not associated with C3a is its chemotactic activity for polymorphonuclear leukocytes 
(Fernandez et al., 1978; Hugli, 1979). 
Once the complement cascade is activated in vivo, C5a appears to be rapidly 
cleaved to a des arg 74 derivative (C5a des arg) by a serum enzyme similar to 
carboxypeptidase B (Bokisch and Muller-Eberhard, 1970). Although C5a des arg is 
spasmogenically inactive (Fernandez et al., 1978) this peptide has been shown to be 
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chemotactically active especially in the presence of normal human serum or plasma 
(Perez et al., 1981). In vitro investigations have demonstrated that as little as 15 
ng /ml  of purified C5a or 150 ng /ml  C5a des arg can effectively induce the 
unidirectional movement of neutrophils (Chenoweth and Hugli, 1980). The potent 
biological activity of minute concentrations of these chemotactic peptides dictate 
that very sensitive assays be developed in order to detect trace quantities of the 
C5 a /C 5a  des arg (C5a antigen) molecules in biological fluids. Therefore, we have 
developed an enzyme-linked immunosorbent assay (ELISA) capable of detecting 
nanogram quantities of C5a antigen. This technique, originally developed by Engvall 
and Perlmann (1971), has proven to be an extremely sensitive immunoassay used to 
quantitate many antigens of biological importance (Engvall and Perlmann, 1972: 
Handley et al., 1982). The following C5a ELISA methodology possesses many 
unique advantages over other quantitative methods: the enzyme conjugates and 
reaction products are stable for long periods of time, the ELISA method can be 
automated and conducted in microtiter plates, finally, the technique avoids the 
problems related to the use of radiolabelled compotmds. 
Materials and Methods 
Isolation of C5a and C5a des arg 
Human C5a was isolated employing immunoadsorbent chromatography accord- 
ing to a modification of the procedure of Manderino et al. (1982). Briefly, normal 
human sera was activated with zymosan in the presence of the serum carboxypepti- 
dase N (SCPN) inhibitor DL-2-mercaptomethyl-3-guandinoethyl-thiopropanoic acid 
(Calbiochem, La Jolla, CA) (Hugli et al., 1981). After the removal of zymosan by 
centrifugation, the activated serum was passed over a 200 ml anti-human C5a 
Sepharose column. The absorbed C5a was eluted with 0.2 M glycine-HCl, pH 2.5, 
concentrated by ultrafihration, and further purified by gel filtration on a Bio-Gel 
P-30 (BioRad Laboratories, Richmond, CA) column (2.5 cm × 90 cm) previously 
equilibrated with 50 mM ammonium formate, 100 mM NaCI, pH 4.5. The purified 
C5a was stored in acid conditions at - 7 0 ° C .  
C5a des arg, formed by the activation of serum complement in the absence of the 
SCPN inhibitor, was purified using the above procedure. In addition, purified C5a 
was subjected to exopeptidase digestion using pancreatic carboxypeptidase B 
(Worthington, Freehold, NJ). Digestion was preformed in 1% NaHCO3, pH 7.8, at 
an enzyme to substrate ratio of 1 : 50 (w/w). After 30 min at 37°C, the incubation 
was terminated by the addition of 0.05 M sodium acetate buffer. 
Isolation of C5 
Human C5 was isolated according to the procedure of Kunkel et al. (1980). 
Antiserum production 
Antibodies used throughout this study were raised in a goat by multisite, 
intramuscular injections of antigen (Manderino et al., 1982). Fifty micrograms of 
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C5a des arg emulsified in complete Freund's adjuvant were used as the initial 
immunogen. The goat was boosted at 4-month intervals and serum collected 10 days 
after each boost. IgG was purified according to the method of Gray et al. (1969). 
Goa t  anti-human C5a des arg was alkaline phosphatase conjugated as previously 
described (Engvall and Perlmann, 1972). 
lmmunodiffusion analysis 
Ouchterlony immunodiffusion was performed in 1% agarose-PBS. Five micro- 
grams of human C5a or C5a des arg, 15/,tg of human C5, or 30/~g anti-human C5a 
des arg were added to wells (in 15 btl volumes) and incubated overnight at 4°C. 
Protein determinations 
Protein concentrations were determined by either the method of Lowry et al. 
(1951), with bovine serum albumin serving as a protein standard, or by ultraviolet 
absorption at 280 nm. 
ELISA procedure 
Wells of microtitration plates (Immulon 1, ' u '  plates; Dynatech Laboratories, 
Richmond, VA) were coated by adding 100 /.tl of a 1:3000 dilution of goat 
anti-human C5a antibody (3.33 t~g/well) in phosphate buffered saline (PBS), pH 
7.2. The coated microtitre plates were covered with parafilm and incubated over- 
night at 4°C. Immediately prior to an assay, the coating solution was removed and 
the wells washed 3 times with PBS, pH 7.2, containing 0.05% Tween 20 and 0.02% 
sodium azide (PTA). After the final rinse, the microtiter plates were inverted on a 
dry paper towel and allowed to drain thoroughly. Serial dilutions of either human 
purified C5a, human C5a des arg, human C5, or activated serum from a number of 
species were made in PTA and 100 ~1 of sample were added to each well. The plates 
were then incubated for 4 h at 4°C. Following 3 additional washes with PTA, 100/~1 
of the alkaline phosphatase conjugated goat anti-human C5a antibody (diluted 
1 : 300 in PTA) was added to each well and incubated for 4 h at 4°C. The plates were 
again washed 3 times with PTA, and 100 ~1 of a 1 m g / m l  solution of disodium 
para-nitrophenyl phosphate (no. 104; Sigma Chemical Co., St. Louis, MO) in 200 
mM carbonate buffer, 4 mM MgCI 2, pH 9.8, was added to each well. The microtiter 
plates were then incubated for a standard period of 100 min in all experiments 
determining C5a antigen levels. The optical density of the fluid in each well was 
determined using a Titertek multiscan microtitre plate reader at 405 nm. It was not 
necessary to stop the enzymatic reaction in each of the 96 wells, because the Titertek 
multiscan can read and print the results of each plate in less than 1 min. All samples 
were analyzed in duplicate. Before reading the optical density, the Titertek reader 
was blanked to a column of wells in a separate plate: each of the wells contained 100 
~1 of the substrate solution. 
Results 
Specificity and immunodiffusion analysis of ELISA components 
The goat polyclonal antibody used throughout these studies was examined for its 
ability to immuno-precipitate C5a, C5a des arg, and C5 in Ouchterlony double 
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Fig. 1. Ouchterlony analysis of (a) immunoadsorbent purified human C5a prepared according to a 
modification of Manderino et al. (1982). (b) human C5a des arg. prepared by carboxypeptidase B 









Fig. 2. Determination of optimal goat anti-human CSa concentration for coating the microtitre wells. 
Wells were coated with various concentrations of antibody. followed by incubation with various dilutions 
of CSa. The enzyme-anti-IgG conjugate was diluted 1 : 300 in PTA. 
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immunodiffusion. In the assay, 3 #g of C5a or C5a des arg, 15/~g of C5, and 30/~g 
of antibody were placed in each of the respective wells. The reactions were then 
developed at 4°C for 16 h. Immunoadsorbent-purified human C5a des arg showed 
lines of identity with immunoadsorbent-purified human C5a when tested against the 
polyclonal antibody (Fig. 1). Human C5 did not react. 
Optimal antibody concentration of antibody for coating microtitre wells 
To determine the optimal concentration of anti-human C5a needed to coat the 
wells, 100 #1 of varying concentrations of polyclonal antibodies in PBS were added 
to each well and incubated at 4°C overnight. After washing thoroughly, each well 
was tested with 100 ~1 of 300 ng /ml  C5a des arg and developed with 100/al of a 
1 : 100 dilution of conjugated antibody. As shown in Fig. 2, 3/~g/well  was found to 
be the optimal concentration for the coating antibody. 
Specificity of the ELISA assay 
To determine the specificity of this ELISA methodology, purified C5a, C5a des 
arg, and native C5 were assayed for specificity of detectable antigen. The ELISA 
assay was shown to be equally specific for either C5a or C5a des arg (Fig. 3). The 
limit of detection for either antigen was approximately 4 ng/ml.  Purified C5 did not 
significantly cross-react in this ELISA assay. To further examine this observation, 2 
/~l/ml of purified human C5 was added to 120 ng /ml  of purified human C5a; 2-fold 
serial dilutions of this mixture was then examined in the ELISA. As shown in Fig. 4, 
the human C5/C5a  mixture demonstrated a dose curve that was nearly identical to 
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Fig. 3. Determination of the specificity of ELISA methodology for C5a, prepared according to a 
modification of the procedure of Manderino et al. (1982) (© ©), and C5a des arg prepared by 
carboxypeptidase B digestion as described in Materials and Methods (e  o). 
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Fig. 4. Determination of the specificity of the ELISA methodology for a mixture of human Cja and 
human C5. Each point represents the optical density obtained by the additive amount of C5a + C5 found 
on the abscissa. 
the dose-response curve of C5a or C5a des arg alone. Thus. levels of C5 antigen 
below 1 pg/ml do not alter the ELISA for C5a antigen detection. Both heat-in- 
activated normal human serum (NHS) and NHS activated with zymosan were 
examined for C5a antigen (Fig. 5). The zymosan-activated NHS had detectable 
levels of antigen even when diluted l/3000. This is in contrast to the heat-in- 
3 2 1 
-log dilution 
Fig. 5. Titration of C5a antigen found in heat-inactivated normal human serum (0 - 0) and normal 
human serum activated with 15 mg/ml zymosan (0 -0). 
TABLE I 
ANALYSIS OF C5a ANTIGEN IN VARIOUS SAMPLES 
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Sample ng C5a antigen/ml + S.E.M. 
Normal human plasma 30+ 5 
Normal human serum 112+ 10 
Normal human serum (56°C. 1 h) 158 ± 63 
Normal human serum + zymosan (25 mg/ml) 3 867 + 32 l 
Normal human serum (56°C. 1 h)+zymosan (25 mg/ml) 108 + 7 
Normal human serum + EDTA + zymosan 122 + 6 
Human C5-deficient serum < 5 
Human C5-deficient serum + zymosan < 7 
Normal rat serum < 2 
Normal rat serum + zymosan (25 mg/ml) 18 + 4 
Normal mouse serum 50+ 7 
Normal mouse serum + zymosan (25 mg/ml) 320 + 15 
Normal rabbit serum 4 + 1 
Normal rabbit serum + zymosan (25 mg/ml) 15 + 3 
activated NHS, which demonst ra ted  little C5a ant igen after a 20-fold dilution. The 
presence of C5a ant igen in NHS may be accounted for by the abili ty of clott ing 
factors to generate C5a-like ant igen from C5 (Wiggins et al., 1981). 
The specificity of the ELISA procedure was also examined using C5-deficient 
h u m a n  serum, EDTA-t rea ted  NHS, and activated serum from various animals.  No 
statistical difference was observed in the C5a ant igen levels from NHS, heat-in- 
activated NHS,  heat- inact ivated NHS activated with zymosan,  or N H S  treated with 
E D T A  and  then activated (Table I). Zymosan-ac t iva ted  rat or rabbi t  serum demon-  
strated no C5a antigen,  while activated mouse serum expressed low levels of cross 
reacting C5a antigen. As a control,  zymosan-act ivated C5 deficient huma n  serum 
conta ined  no detectable C5a antigen. In  contrast,  the zymosan-act ivated N H S  was 
found to possess very high levels of C5a antigen;  the levels of ant igen exceeded 3.5 
t t g / m l  of activated serum. 
Discussion 
Proteins of the complement  cascade are known to play a significant biological 
role as mediators of in f lammatory  processes. Considerable  experimental  and  clinical 
evidence has accumulated to implicate split products  of complement ,  especially C5a, 
as the genesis of many  pathological consequences (Hammerschmid t  et al., 1980). 
Most  of these studies have relied on either bioassays such as po lymorphonuclear  
leukocyte (PMN)  aggregation (Craddock et al., 1977a), and chemotaxis (Mayer  et 
al., 1976), d iminu t ion  of peripheral  PMN counts,  (Craddock, 1977b), or immunoe-  
lectrophoresis (Hammerschmidt ,  1980). In the latter technique samples were ex- 
amined  only for specific complement  conversion products.  
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Using PMN aggregation as a bioassay, Hammerschmidt et al. (1980) examined 
the plasma from a number of patients at risk for Adult Respiratory Distress 
Syndrome (ARDS). In this study, a significant correlation was observed between the 
presence in plasma of PMN-aggregating material and the subsequent development 
of ARDS. The generation of C5a in acute cardiopulmonary complication due to 
cellophane-membrane hemodialysis has been examined using changes in arterial 
blood PMN levels and changes in arterial oxygen tension as indices (Craddock, 
1977a). During the first 30 min of hemodialysis, patients' neutrophil counts fell 
precipitously resulting in a transient neutropenia. Arterial oxygen tension also 
dropped during this time period indicating significant changes in pulmonary func- 
tions. Although all of the above studies and assays are important means to 
determine indirectly C5a or C5a des arg activity, none of these assays directly or 
specifically quantitate antigen levels of this important C5 product. Recent clinical 
investigations by Nelson et al. (1983) have examined plasma levels of C5a des arg 
antigen over various time periods from burn patients. Employing a radioimmunoas- 
say developed by Hugli and Chenoweth (1980), levels of C5a des arg antigen present 
in burn patients' plasma was examined over a 30-day period. Peak C5a des arg 
antigen was found at day 9 post-burn injury~ at which time more than 60 ng /ml  of 
antigen was found in the plasma. Interestingly, this peak in plasma C5a des arg 
antigen correlated with a desensitization effect on the patients PMN. In an addi- 
tional clinical study, radioimmunoassays for both C3a and C5a antigen were used to 
quantitate levels of these complement products in the plasma of patients undergoing 
cardiopulmonary bypass (Chenoweth et al., 1981). Although C3a levels were signifi- 
cantly elevated during the bypass operation, C5a levels did not increase significantly. 
The latter finding was observed even though significant neutropenia was found in 
the patients during bypass: a phenomenon consistent with pulmonary vascular 
sequestration induced by C5a-activated PMNs. 
In this report, we have described a specific and extremely sensitive microELISA 
procedure for the detection of human C5a /C5a  des arg antigen. As shown in Fig. 3, 
both C5a and C5a des arg were found to react equally well in the ELISA assay. The 
C5a des arg used in this analysis was prepared by either purifying C5a des arg from 
serum in the absence of a SCPN-blocking agent or by purifying C5a and treating 
this peptide with SCPB. In either case, the polyclonal antibody failed to distinguish 
between C5a and C5a des arg antigen. The cross-reactivity between C5a and the 
parent C5 molecule was extremely low (Fig. 4). 
In initial studies, we examined the ability of the ELISA to detect C5a /C5a  des 
arg antigen in NHS, normal human plasma, and zymosan-activated serum (Table I). 
Our findings clearly demonstrate that normal human plasma contains significantly 
lower levels of antigen than NHS. This observation is in agreement with the 
radioimmunoassay data generated by Hugli and Chenoweth (1980). In both studies, 
EDTA-heparinized plasma was shown to contain about one quarter the C5a antigen 
as compared to NHS. The elevated levels of C5a in serum is consistent with the 
findings of Wiggins et al. (1981), who demonstrated the ability of specific proteins of 
the coagulation cascade to generate C5a-like material from rabbit C5. This observa- 
tion may be important, since it could link activation of the coagulation to the 
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complement cascade in various inflammatory reactions. In an effort to examine the 
ability of the human C5a ELISA technique to detect C5a-like antigen from various 
species, we studied zymosan-activated serum from rats, mice and rabbits. The 
polyclonal anti-human C5a did not cross react with activated serum from these 
species (Table I) to any significant extent. Therefore, the human ELISA was neither 
specific nor sensitive for the other species. 
The ability to quantitate levels of C5a in plasma and other biological fluids 
provides a sensitive assessment of complement activation and C5 cleavage in various 
disease states. The detection of nanogram levels of C5a by the ELISA methodology 
permits the quantitation of this biologically active peptide beyond the limits of both 
bioassays and other alternative methods, an important consideration, since it is well 
known that this peptide is an extremely potent mediator active at nanomolar 
concentrations. The appearance of C5a through complement activation appears to 
correlate well with many phyogistic processes including autoimmune diseases. Al- 
though the potential of a specific and sensitive ELISA technique for quantitating 
human C5a is promising, the applicability of this method to determine C 5 a / C 5 a  des 
arg antigen in plasma and other biological fluids will definitely await further studies. 
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